This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | hsa-miR-21-5p | ABAT | 1.51 | 0 | -2.16 | 0 | MirTarget | -0.93 | 0 | NA | |
2 | hsa-miR-21-5p | ABCA1 | 1.51 | 0 | -1.1 | 0 | mirMAP | -0.29 | 0 | NA | |
3 | hsa-miR-21-5p | ABCA10 | 1.51 | 0 | -1.06 | 4.0E-5 | mirMAP | -0.45 | 0 | NA | |
4 | hsa-miR-21-5p | ABCD3 | 1.51 | 0 | -0.9 | 0 | miRNAWalker2 validate | -0.38 | 0 | NA | |
5 | hsa-miR-21-5p | ACAT1 | 1.51 | 0 | -1.62 | 0 | miRNAWalker2 validate | -0.62 | 0 | NA | |
6 | hsa-miR-21-5p | ACBD5 | 1.51 | 0 | -0.75 | 0 | miRNAWalker2 validate; miRNATAP | -0.33 | 0 | NA | |
7 | hsa-miR-21-5p | ACVR2A | 1.51 | 0 | -0.55 | 0 | miRNATAP | -0.17 | 0 | NA | |
8 | hsa-miR-21-5p | AIM1 | 1.51 | 0 | -1.46 | 0 | miRNAWalker2 validate | -0.35 | 0 | NA | |
9 | hsa-miR-21-5p | AKAP6 | 1.51 | 0 | -0.97 | 0 | MirTarget | -0.54 | 0 | NA | |
10 | hsa-miR-21-5p | AKAP9 | 1.51 | 0 | -0.79 | 0 | miRNAWalker2 validate | -0.29 | 0 | NA | |
11 | hsa-miR-21-5p | AKIRIN1 | 1.51 | 0 | -0.73 | 0 | miRNATAP | -0.13 | 0.00038 | NA | |
12 | hsa-miR-21-5p | AKT2 | 1.51 | 0 | -0.34 | 1.0E-5 | miRNAWalker2 validate | -0.25 | 0 | NA | |
13 | hsa-miR-21-5p | ANKRD28 | 1.51 | 0 | -0.36 | 1.0E-5 | miRNAWalker2 validate | -0.17 | 0 | NA | |
14 | hsa-miR-21-5p | ANKRD46 | 1.51 | 0 | -0.78 | 0 | miRNAWalker2 validate; miRTarBase | -0.41 | 0 | 21219636 | Knockdown of miR-21 significantly increased the expression of ANKRD46 at both mRNA and protein levels; ANKRD46 is newly identified as a direct target of miR-21 in BC |
15 | hsa-miR-21-5p | ANO3 | 1.51 | 0 | -2.3 | 0 | mirMAP | -0.98 | 0 | NA | |
16 | hsa-miR-21-5p | AP1AR | 1.51 | 0 | -0.61 | 0 | MirTarget; miRNATAP | -0.25 | 0 | NA | |
17 | hsa-miR-21-5p | APC | 1.51 | 0 | -0.18 | 0.06792 | miRNAWalker2 validate | -0.17 | 0 | 23773491; 24832083 | The prognostic significance of APC gene mutation and miR 21 expression in advanced stage colorectal cancer; The aim of this study was to analyse the association of APC gene mutation and miR-21 expression with clinical outcome in CRC patients; APC gene mutation and expression of APC and miR-21 were analysed by direct DNA sequencing and real-time reverse transcription polymerase chain reaction; APC gene expression was low in CRC and negatively correlated with miR-21 expression and gene mutation; In Taiwan downregulation of the APC gene in CRC correlated with gene mutation and miR-21 upregulation; APC mutation and miR-21 expression could be used to predict the clinical outcome of CRC especially in patients with advanced disease;MicroRNA 21 promotes tumour malignancy via increased nuclear translocation of β catenin and predicts poor outcome in APC mutated but not in APC wild type colorectal cancer; However in our preliminary data the prognostic value of miR-21 levels was observed only in adenomatous polyposis coli APC-mutated tumours not in APC-wild-type tumours; We enrolled 165 colorectal tumour to determine APC mutation miR-21 levels and nuclear β-catenin expression by direct sequencing real-time PCR and immunohistochemistry |
18 | hsa-miR-21-5p | APOLD1 | 1.51 | 0 | 0.45 | 0.00929 | miRNAWalker2 validate | -0.18 | 0.00545 | NA | |
19 | hsa-miR-21-5p | ARHGAP21 | 1.51 | 0 | -0.09 | 0.37274 | miRNAWalker2 validate | -0.11 | 0.00286 | NA | |
20 | hsa-miR-21-5p | ARHGAP24 | 1.51 | 0 | -0.99 | 0 | MirTarget; miRNATAP | -0.36 | 0 | NA | |
21 | hsa-miR-21-5p | ARHGAP32 | 1.51 | 0 | -0.2 | 0.09921 | MirTarget | -0.29 | 0 | NA | |
22 | hsa-miR-21-5p | ARHGEF12 | 1.51 | 0 | -0.86 | 0 | miRNAWalker2 validate; MirTarget | -0.26 | 0 | NA | |
23 | hsa-miR-21-5p | ARID4A | 1.51 | 0 | -0.9 | 0 | miRNAWalker2 validate | -0.43 | 0 | NA | |
24 | hsa-miR-21-5p | ART4 | 1.51 | 0 | -1.74 | 0 | mirMAP | -0.48 | 1.0E-5 | NA | |
25 | hsa-miR-21-5p | ASPN | 1.51 | 0 | -1.64 | 0 | MirTarget; miRNATAP | -0.2 | 0.04902 | NA | |
26 | hsa-miR-21-5p | ATAD2B | 1.51 | 0 | -0.06 | 0.4791 | miRNAWalker2 validate | -0.14 | 3.0E-5 | NA | |
27 | hsa-miR-21-5p | ATF2 | 1.51 | 0 | -0.24 | 0.15619 | miRNAWalker2 validate | -0.18 | 0.00336 | NA | |
28 | hsa-miR-21-5p | ATMIN | 1.51 | 0 | -0.37 | 0 | miRNAWalker2 validate | -0.12 | 0 | NA | |
29 | hsa-miR-21-5p | ATP11B | 1.51 | 0 | -0.35 | 0.00133 | miRNAWalker2 validate | -0.16 | 4.0E-5 | NA | |
30 | hsa-miR-21-5p | ATP2B2 | 1.51 | 0 | -0.4 | 0.15518 | mirMAP | -0.24 | 0.01837 | NA | |
31 | hsa-miR-21-5p | ATRN | 1.51 | 0 | 0.12 | 0.34173 | miRNATAP | -0.17 | 0.00015 | NA | |
32 | hsa-miR-21-5p | ATRNL1 | 1.51 | 0 | -2.28 | 0 | MirTarget | -0.65 | 8.0E-5 | NA | |
33 | hsa-miR-21-5p | ATRX | 1.51 | 0 | -0.07 | 0.48759 | miRNAWalker2 validate | -0.1 | 0.00335 | NA | |
34 | hsa-miR-21-5p | ATXN3 | 1.51 | 0 | -0.29 | 0.00037 | mirMAP | -0.22 | 0 | NA | |
35 | hsa-miR-21-5p | AUTS2 | 1.51 | 0 | -1.2 | 0 | miRNAWalker2 validate | -0.85 | 0 | NA | |
36 | hsa-miR-21-5p | BACE1 | 1.51 | 0 | -0.45 | 0 | mirMAP | -0.29 | 0 | NA | |
37 | hsa-miR-21-5p | BCL6 | 1.51 | 0 | -0.38 | 0.00305 | miRNAWalker2 validate | -0.19 | 6.0E-5 | NA | |
38 | hsa-miR-21-5p | BDH2 | 1.51 | 0 | -1.59 | 0 | miRNAWalker2 validate | -0.57 | 0 | NA | |
39 | hsa-miR-21-5p | BMP2K | 1.51 | 0 | -0.82 | 0 | mirMAP | -0.12 | 0.00963 | NA | |
40 | hsa-miR-21-5p | BMPR2 | 1.51 | 0 | -0.74 | 0 | miRNAWalker2 validate; miRTarBase; MirTarget | -0.28 | 0 | NA | |
41 | hsa-miR-21-5p | BRD1 | 1.51 | 0 | -0.22 | 0.01173 | MirTarget | -0.1 | 0.0018 | NA | |
42 | hsa-miR-21-5p | C16orf52 | 1.51 | 0 | -0.5 | 0 | miRNATAP | -0.29 | 0 | NA | |
43 | hsa-miR-21-5p | C1orf226 | 1.51 | 0 | 0.29 | 0.07217 | mirMAP | -0.13 | 0.03584 | NA | |
44 | hsa-miR-21-5p | CADM2 | 1.51 | 0 | -2.32 | 0 | mirMAP; miRNATAP | -0.38 | 0.00648 | NA | |
45 | hsa-miR-21-5p | CALD1 | 1.51 | 0 | -0.53 | 0 | miRNAWalker2 validate; MirTarget | -0.27 | 0 | NA | |
46 | hsa-miR-21-5p | CASC4 | 1.51 | 0 | -0.46 | 0 | miRNATAP | -0.14 | 8.0E-5 | NA | |
47 | hsa-miR-21-5p | CCDC121 | 1.51 | 0 | 0.09 | 0.43018 | MirTarget | -0.21 | 0 | NA | |
48 | hsa-miR-21-5p | CCDC152 | 1.51 | 0 | -1.09 | 0 | mirMAP | -0.61 | 0 | NA | |
49 | hsa-miR-21-5p | CCNG1 | 1.51 | 0 | -0.05 | 0.64033 | miRNAWalker2 validate | -0.13 | 0.00024 | NA | |
50 | hsa-miR-21-5p | CLCN5 | 1.51 | 0 | -0.78 | 0 | miRNAWalker2 validate; mirMAP | -0.33 | 0 | NA | |
51 | hsa-miR-21-5p | CLOCK | 1.51 | 0 | -0.53 | 0.00745 | miRNAWalker2 validate | -0.26 | 0.00029 | NA | |
52 | hsa-miR-21-5p | CNTFR | 1.51 | 0 | -3.51 | 0 | miRNATAP | -1.1 | 0 | NA | |
53 | hsa-miR-21-5p | COBLL1 | 1.51 | 0 | -1.47 | 0 | miRNAWalker2 validate | -0.8 | 0 | NA | |
54 | hsa-miR-21-5p | CPEB3 | 1.51 | 0 | -2.74 | 0 | miRNAWalker2 validate; MirTarget; miRNATAP | -0.98 | 0 | NA | |
55 | hsa-miR-21-5p | CREBL2 | 1.51 | 0 | -0.86 | 0 | miRNATAP | -0.28 | 0 | NA | |
56 | hsa-miR-21-5p | CRIM1 | 1.51 | 0 | -0.43 | 0.03963 | miRNATAP | -0.15 | 0.04655 | NA | |
57 | hsa-miR-21-5p | CSNK1A1 | 1.51 | 0 | -0.34 | 0 | miRNAWalker2 validate | -0.1 | 0 | NA | |
58 | hsa-miR-21-5p | CYBRD1 | 1.51 | 0 | -1.29 | 0 | miRNAWalker2 validate | -0.31 | 6.0E-5 | NA | |
59 | hsa-miR-21-5p | CYP4V2 | 1.51 | 0 | -1.71 | 0 | miRNAWalker2 validate | -0.71 | 0 | NA | |
60 | hsa-miR-21-5p | DAAM1 | 1.51 | 0 | -0.82 | 3.0E-5 | miRNAWalker2 validate | -0.58 | 0 | NA | |
61 | hsa-miR-21-5p | DCAF10 | 1.51 | 0 | -0.27 | 0.00016 | miRNAWalker2 validate | -0.19 | 0 | NA | |
62 | hsa-miR-21-5p | DCAF8 | 1.51 | 0 | -0.03 | 0.75166 | miRNAWalker2 validate | -0.16 | 0 | NA | |
63 | hsa-miR-21-5p | DDAH1 | 1.51 | 0 | -0.92 | 0 | miRNAWalker2 validate | -0.39 | 0 | 26741162 | In vitro study showed QTsome/AM-21 induced upregulation of miR-21 targets including PTEN and DDAH1 in A549 cells while increasing their sensitivity toward paclitaxel PTX |
64 | hsa-miR-21-5p | DDR2 | 1.51 | 0 | -0.84 | 0.00128 | miRNAWalker2 validate | -0.3 | 0.00149 | NA | |
65 | hsa-miR-21-5p | DDX3X | 1.51 | 0 | -0.7 | 0 | miRNAWalker2 validate | -0.2 | 0 | NA | |
66 | hsa-miR-21-5p | DLG1 | 1.51 | 0 | -0.14 | 0.08412 | miRNAWalker2 validate | -0.19 | 0 | NA | |
67 | hsa-miR-21-5p | DMD | 1.51 | 0 | -1.66 | 0 | miRNAWalker2 validate | -0.77 | 0 | NA | |
68 | hsa-miR-21-5p | DOCK4 | 1.51 | 0 | -0.2 | 0.07305 | miRNAWalker2 validate; miRTarBase | -0.11 | 0.00485 | NA | |
69 | hsa-miR-21-5p | DOCK5 | 1.51 | 0 | -0.64 | 0.00098 | miRNAWalker2 validate; miRTarBase | -0.25 | 0.00043 | NA | |
70 | hsa-miR-21-5p | DOK6 | 1.51 | 0 | -1.91 | 0 | mirMAP | -0.47 | 8.0E-5 | NA | |
71 | hsa-miR-21-5p | DST | 1.51 | 0 | -0.38 | 0.00155 | mirMAP | -0.19 | 1.0E-5 | 22403704 | While the EDCs and estrogen similarly altered the expression of multiple microRNAs in MCF-7 cells including miR-21 differential patterns of microRNA expression were induced by DDT and BPA compared to estrogen |
72 | hsa-miR-21-5p | DUSP10 | 1.51 | 0 | -1.25 | 0 | miRNAWalker2 validate; miRTarBase | -0.34 | 0 | NA | |
73 | hsa-miR-21-5p | EGFR | 1.51 | 0 | -1.02 | 0 | miRNAWalker2 validate; miRTarBase | -0.44 | 0 | 24198203; 20113523; 24012640; 24331411; 26563758; 19597153; 26026961; 20048743 | In radically resected NSCLC patients the expression levels of miR-21 10b in patients with EGFR mutation were much higher than those without mutation;Thus the miR-21 inhibitor might interrupt the activity of EGFR pathways independently of PTEN status;Further the expression of miR-21 is regulated by EGFR via the activation of β-catenin and AP-1; These data indicate that a feedback loop exists between miR-21 and EGFR; These results clarify a novel association between miR-21 and EGFR in the regulation of cancer cell progression;MiR 21 overexpression is associated with acquired resistance of EGFR TKI in non small cell lung cancer;Higher expression levels of miR-21 AmiR-27a and miR-218 detected in this study suggest potential roles of these miRNAs in primary resistance to EGFR-TKI in advanced NSCLC patients with EGFR exon 19 deletion mutations;MiR 21 is an EGFR regulated anti apoptotic factor in lung cancer in never smokers; The changes in expression of some of these miRNAs including miR-21 were more remarkable in cases with EGFR mutations than in those without these mutations; In the never-smoker-derived lung adenocarcinoma cell line H3255 with mutant EGFR and high levels of p-EGFR and miR-21 antisense inhibition of miR-21 enhanced AG1478-induced apoptosis; In a never-smoker-derived adenocarcinoma cell line H441 with wild-type EGFR the antisense miR-21 not only showed the additive effect with AG1478 but also induced apoptosis by itself; These results suggest that aberrantly increased expression of miR-21 which is enhanced further by the activated EGFR signaling pathway plays a significant role in lung carcinogenesis in never-smokers as well as in smokers and is a potential therapeutic target in both EGFR-mutant and wild-type cases;Nickel may contribute to EGFR mutation and synergistically promotes tumor invasion in EGFR mutated lung cancer via nickel induced microRNA 21 expression;Downregulation of miR 21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status |
74 | hsa-miR-21-5p | EIF1AX | 1.51 | 0 | -0.29 | 0.00114 | miRNATAP | -0.23 | 0 | NA | |
75 | hsa-miR-21-5p | EIF4EBP2 | 1.51 | 0 | -0.11 | 0.27493 | miRNAWalker2 validate | -0.25 | 0 | NA | |
76 | hsa-miR-21-5p | EIF5 | 1.51 | 0 | -0.72 | 0 | miRNAWalker2 validate | -0.26 | 0 | NA | |
77 | hsa-miR-21-5p | ELF2 | 1.51 | 0 | -0.39 | 0 | MirTarget; miRNATAP | -0.17 | 0 | NA | |
78 | hsa-miR-21-5p | ENTPD4 | 1.51 | 0 | -0.41 | 0.00079 | mirMAP | -0.14 | 0.00192 | NA | |
79 | hsa-miR-21-5p | EPM2A | 1.51 | 0 | -1.16 | 0 | miRNAWalker2 validate | -0.56 | 0 | NA | |
80 | hsa-miR-21-5p | EPM2AIP1 | 1.51 | 0 | -0.3 | 0.00244 | mirMAP | -0.28 | 0 | NA | |
81 | hsa-miR-21-5p | ESYT2 | 1.51 | 0 | -0.17 | 0.03903 | miRNAWalker2 validate; MirTarget | -0.12 | 6.0E-5 | NA | |
82 | hsa-miR-21-5p | EXOC5 | 1.51 | 0 | -0.38 | 0 | miRNAWalker2 validate | -0.2 | 0 | NA | |
83 | hsa-miR-21-5p | FAM107B | 1.51 | 0 | -0.78 | 0 | miRNATAP | -0.24 | 0 | NA | |
84 | hsa-miR-21-5p | FAM126B | 1.51 | 0 | -0.64 | 0 | miRNAWalker2 validate | -0.28 | 0 | NA | |
85 | hsa-miR-21-5p | FAM46A | 1.51 | 0 | -1.45 | 0 | miRNAWalker2 validate; miRNATAP | -0.31 | 0 | NA | |
86 | hsa-miR-21-5p | FAM63B | 1.51 | 0 | -0.54 | 0.00241 | miRNATAP | -0.21 | 0.00123 | NA | |
87 | hsa-miR-21-5p | FAS | 1.51 | 0 | -1.02 | 0 | miRNAWalker2 validate | -0.35 | 0 | 24710931 | miR 21 targets Fas ligand mediated apoptosis in breast cancer cell line MCF 7 |
88 | hsa-miR-21-5p | FBXL17 | 1.51 | 0 | -0.25 | 0.00489 | miRNAWalker2 validate; miRNATAP | -0.19 | 0 | NA | |
89 | hsa-miR-21-5p | FBXO28 | 1.51 | 0 | -0.5 | 0 | MirTarget | -0.19 | 0 | NA | |
90 | hsa-miR-21-5p | FBXO3 | 1.51 | 0 | -0.54 | 0 | miRNAWalker2 validate | -0.27 | 0 | NA | |
91 | hsa-miR-21-5p | FERMT2 | 1.51 | 0 | -1.17 | 0 | miRNAWalker2 validate | -0.47 | 0 | NA | |
92 | hsa-miR-21-5p | FGD4 | 1.51 | 0 | -1.16 | 0 | MirTarget | -0.49 | 0 | NA | |
93 | hsa-miR-21-5p | FGF2 | 1.51 | 0 | -1.09 | 0.00032 | mirMAP | -0.44 | 6.0E-5 | NA | |
94 | hsa-miR-21-5p | FILIP1L | 1.51 | 0 | -1.19 | 0 | miRNAWalker2 validate | -0.22 | 0.00092 | NA | |
95 | hsa-miR-21-5p | FMR1 | 1.51 | 0 | 0.02 | 0.84822 | miRNAWalker2 validate | -0.18 | 0 | NA | |
96 | hsa-miR-21-5p | FOXN3 | 1.51 | 0 | -0.43 | 6.0E-5 | miRNAWalker2 validate; mirMAP | -0.36 | 0 | NA | |
97 | hsa-miR-21-5p | FOXP2 | 1.51 | 0 | -3.25 | 0 | mirMAP | -0.74 | 0 | NA | |
98 | hsa-miR-21-5p | FREM2 | 1.51 | 0 | -5.81 | 0 | mirMAP | -1.22 | 0 | NA | |
99 | hsa-miR-21-5p | FRMD3 | 1.51 | 0 | 0.2 | 0.5219 | MirTarget | -0.38 | 0.00068 | NA | |
100 | hsa-miR-21-5p | FZD4 | 1.51 | 0 | -0.35 | 0.01097 | mirMAP | -0.32 | 0 | NA | |
101 | hsa-miR-21-5p | GFOD1 | 1.51 | 0 | -0.74 | 0 | mirMAP | -0.37 | 0 | NA | |
102 | hsa-miR-21-5p | GLCCI1 | 1.51 | 0 | -0.29 | 0.0401 | miRNAWalker2 validate; MirTarget; miRNATAP | -0.42 | 0 | NA | |
103 | hsa-miR-21-5p | GLYR1 | 1.51 | 0 | -0.17 | 0.02754 | miRNATAP | -0.1 | 0.00024 | NA | |
104 | hsa-miR-21-5p | GNAQ | 1.51 | 0 | -0.39 | 1.0E-5 | miRNAWalker2 validate | -0.25 | 0 | NA | |
105 | hsa-miR-21-5p | GNE | 1.51 | 0 | -1.82 | 0 | miRNAWalker2 validate | -0.76 | 0 | NA | |
106 | hsa-miR-21-5p | GOLGA4 | 1.51 | 0 | -0.24 | 0.01863 | miRNAWalker2 validate | -0.25 | 0 | NA | |
107 | hsa-miR-21-5p | GPAM | 1.51 | 0 | -0.47 | 0.0638 | miRNAWalker2 validate; mirMAP | -0.63 | 0 | NA | |
108 | hsa-miR-21-5p | GRAMD3 | 1.51 | 0 | -0.64 | 0 | MirTarget | -0.27 | 0 | NA | |
109 | hsa-miR-21-5p | GTF2A1 | 1.51 | 0 | -0.69 | 0.00536 | miRNAWalker2 validate | -0.43 | 0 | NA | |
110 | hsa-miR-21-5p | GTF2I | 1.51 | 0 | -0.01 | 0.96805 | miRNAWalker2 validate | -0.23 | 0.00076 | NA | |
111 | hsa-miR-21-5p | GXYLT1 | 1.51 | 0 | -0.35 | 3.0E-5 | mirMAP | -0.17 | 0 | NA | |
112 | hsa-miR-21-5p | HBP1 | 1.51 | 0 | -0.36 | 2.0E-5 | miRNATAP | -0.24 | 0 | 26282675 | MicroRNA 21 is a potential link between non alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1 p53 Srebp1c pathway; Further studies revealed that Hbp1 was a novel target of microRNA-21 and a transcriptional activator of p53 |
113 | hsa-miR-21-5p | HECTD1 | 1.51 | 0 | -0.51 | 0 | miRNAWalker2 validate | -0.38 | 0 | NA | |
114 | hsa-miR-21-5p | HHIP | 1.51 | 0 | -5.86 | 0 | mirMAP | -1.12 | 0 | NA | |
115 | hsa-miR-21-5p | HIPK1 | 1.51 | 0 | -0.16 | 0.1272 | mirMAP | -0.11 | 0.00449 | NA | |
116 | hsa-miR-21-5p | HIPK3 | 1.51 | 0 | -1.5 | 0 | MirTarget | -0.58 | 0 | NA | |
117 | hsa-miR-21-5p | HPS5 | 1.51 | 0 | -1.54 | 0 | miRNAWalker2 validate | -0.36 | 0 | NA | |
118 | hsa-miR-21-5p | HS3ST3B1 | 1.51 | 0 | -2.61 | 0 | miRNAWalker2 validate | -0.98 | 0 | NA | |
119 | hsa-miR-21-5p | HSD17B4 | 1.51 | 0 | -0.64 | 1.0E-5 | MirTarget | -0.49 | 0 | NA | |
120 | hsa-miR-21-5p | IDS | 1.51 | 0 | -0.55 | 0 | mirMAP | -0.1 | 0.01298 | NA | |
121 | hsa-miR-21-5p | IL6R | 1.51 | 0 | -0.2 | 0.38255 | MirTarget; miRNATAP | -0.54 | 0 | NA | |
122 | hsa-miR-21-5p | IL6ST | 1.51 | 0 | -1.92 | 0 | mirMAP | -0.64 | 0 | NA | |
123 | hsa-miR-21-5p | ING3 | 1.51 | 0 | -0.22 | 0.01365 | MirTarget | -0.18 | 0 | NA | |
124 | hsa-miR-21-5p | INSR | 1.51 | 0 | -0.28 | 0.00786 | mirMAP | -0.13 | 0.00046 | 24804226; 27220494; 21618027 | Downregulation of miR-21 in radioresistant NSCLC A549 cells inhibited the colony-forming ability and proliferation of A549 cells after IR; Moreover silencing miR-21 enhanced apoptosis of A549 cells induced by IR accompanied by decreased phosphorylated-Akt protein level; However PI3K activator IGF-1 reversed suppression of phosphorylated-Akt protein level and promotion of apoptosis of A549 cells after IR caused by miR-21 knockdown; Silencing miR-21 in radioresistant NSCLC A549 cells sensitized them to IR by inhibiting cell proliferation and enhancing cell apoptosis through inhibition of PI3K/Akt signaling pathway;In addition we also demonstrated that miR-21 confers decreased autophagy in cervical cancer cells after IR via the Akt-mTOR signaling pathway;In this study we found that miR-21 expression was upregulated in response to ionizing radiation IR in U251 cells which suggested that miR-21 could be involved in the response of U251 cells to radiation; We showed that a miR-21 inhibitor enhanced IR-induced glioblastoma cell growth arrest and increased the level of apoptosis which was probably caused by abrogation of the G2-M arrest induced by IR |
125 | hsa-miR-21-5p | INTS6 | 1.51 | 0 | -0.65 | 0 | MirTarget | -0.23 | 0 | NA | |
126 | hsa-miR-21-5p | IPP | 1.51 | 0 | -0.12 | 0.33175 | miRNAWalker2 validate | -0.15 | 0.00067 | NA | |
127 | hsa-miR-21-5p | IREB2 | 1.51 | 0 | -0.37 | 1.0E-5 | miRNAWalker2 validate | -0.22 | 0 | NA | |
128 | hsa-miR-21-5p | ITGA1 | 1.51 | 0 | -0.68 | 0 | mirMAP | -0.32 | 0 | NA | |
129 | hsa-miR-21-5p | JMY | 1.51 | 0 | -0.07 | 0.48262 | miRNAWalker2 validate; mirMAP | -0.17 | 1.0E-5 | NA | |
130 | hsa-miR-21-5p | KBTBD6 | 1.51 | 0 | -0.19 | 0.03786 | miRNAWalker2 validate; MirTarget | -0.21 | 0 | NA | |
131 | hsa-miR-21-5p | KBTBD7 | 1.51 | 0 | -0.94 | 0 | miRNAWalker2 validate | -0.54 | 0 | NA | |
132 | hsa-miR-21-5p | KCNA3 | 1.51 | 0 | -1.97 | 0 | miRNATAP | -0.3 | 0.00296 | NA | |
133 | hsa-miR-21-5p | KIAA0355 | 1.51 | 0 | 0.03 | 0.72841 | MirTarget | -0.15 | 0 | NA | |
134 | hsa-miR-21-5p | KIAA1671 | 1.51 | 0 | -0.84 | 0 | mirMAP | -0.16 | 0.00035 | NA | |
135 | hsa-miR-21-5p | KLF12 | 1.51 | 0 | -0.86 | 0 | mirMAP | -0.55 | 0 | NA | |
136 | hsa-miR-21-5p | KLF3 | 1.51 | 0 | -0.61 | 0 | miRNATAP | -0.23 | 0 | NA | |
137 | hsa-miR-21-5p | KLF6 | 1.51 | 0 | -1.44 | 0 | miRNATAP | -0.27 | 1.0E-5 | NA | |
138 | hsa-miR-21-5p | KLF9 | 1.51 | 0 | -1.36 | 0 | miRNAWalker2 validate | -0.61 | 0 | NA | |
139 | hsa-miR-21-5p | KLHL15 | 1.51 | 0 | -1.44 | 0 | miRNAWalker2 validate; miRNATAP | -0.66 | 0 | NA | |
140 | hsa-miR-21-5p | KLHL24 | 1.51 | 0 | -0.4 | 6.0E-5 | miRNAWalker2 validate | -0.3 | 0 | NA | |
141 | hsa-miR-21-5p | KLHL4 | 1.51 | 0 | -1.09 | 0 | mirMAP | -0.18 | 0.03456 | NA | |
142 | hsa-miR-21-5p | LAMP2 | 1.51 | 0 | -0.14 | 0.20334 | miRNAWalker2 validate | -0.14 | 0.00074 | NA | |
143 | hsa-miR-21-5p | LATS1 | 1.51 | 0 | -0.73 | 4.0E-5 | miRNAWalker2 validate | -0.26 | 7.0E-5 | 25769949 | miR 21 modulates resistance of HR HPV positive cervical cancer cells to radiation through targeting LATS1; By using dual luciferase assay we verified a binding site between miR-21 and 3'-UTR of large tumor suppressor kinase 1 LATS1; Through direct binding miR-21 can regulate LATS1 expression in cervical cancer cells; LATS1 overexpression can reverse miR-21 induced higher colony formation rate and also reduced miR-21 induced S phase accumulation and G2/M phase block reduction under radiation treatment |
144 | hsa-miR-21-5p | LCOR | 1.51 | 0 | -0.83 | 0.00038 | mirMAP | -0.3 | 0.00043 | NA | |
145 | hsa-miR-21-5p | LCORL | 1.51 | 0 | -0.47 | 0.00013 | miRNAWalker2 validate; miRNATAP | -0.17 | 0.00014 | NA | |
146 | hsa-miR-21-5p | LEMD3 | 1.51 | 0 | -0.24 | 0.00152 | miRNATAP | -0.12 | 1.0E-5 | NA | |
147 | hsa-miR-21-5p | LIFR | 1.51 | 0 | -3.55 | 0 | miRNAWalker2 validate | -0.97 | 0 | NA | |
148 | hsa-miR-21-5p | LIN7C | 1.51 | 0 | -0.78 | 0 | miRNAWalker2 validate | -0.32 | 0 | NA | |
149 | hsa-miR-21-5p | LMBR1 | 1.51 | 0 | -0.13 | 0.15477 | miRNAWalker2 validate | -0.12 | 0.00014 | NA | |
150 | hsa-miR-21-5p | LPA | 1.51 | 0 | -3.96 | 0 | MirTarget | -1.32 | 0 | 26098771 | DNA microarray and real-time PCR analyses further demonstrated that LPA up-regulated the oncomiR miR-21 through an LPA1/Pi3K/ZEB1-dependent mechanism |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 65 | 1784 | 2.123e-08 | 9.879e-05 |
2 | PROTEIN PHOSPHORYLATION | 42 | 944 | 5.05e-08 | 0.0001175 |
3 | REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS | 18 | 229 | 1.707e-07 | 0.0002648 |
4 | INTRACELLULAR SIGNAL TRANSDUCTION | 56 | 1572 | 4.975e-07 | 0.0005787 |
5 | PHOSPHORYLATION | 46 | 1228 | 1.56e-06 | 0.001452 |
6 | REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 55 | 1656 | 5.379e-06 | 0.002276 |
7 | POSITIVE REGULATION OF BIOSYNTHETIC PROCESS | 59 | 1805 | 3.808e-06 | 0.002276 |
8 | NEGATIVE REGULATION OF NITROGEN COMPOUND METABOLIC PROCESS | 52 | 1517 | 4.143e-06 | 0.002276 |
9 | POSITIVE REGULATION OF GENE EXPRESSION | 57 | 1733 | 4.742e-06 | 0.002276 |
10 | ENSHEATHMENT OF NEURONS | 10 | 91 | 5.161e-06 | 0.002276 |
11 | AXON ENSHEATHMENT | 10 | 91 | 5.161e-06 | 0.002276 |
12 | PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS | 62 | 1977 | 7.794e-06 | 0.003011 |
13 | TISSUE DEVELOPMENT | 51 | 1518 | 9.058e-06 | 0.003011 |
14 | NEGATIVE REGULATION OF CELL COMMUNICATION | 43 | 1192 | 9.046e-06 | 0.003011 |
15 | NEGATIVE REGULATION OF GENE EXPRESSION | 50 | 1493 | 1.222e-05 | 0.003554 |
16 | REGULATION OF CELL DIFFERENTIATION | 50 | 1492 | 1.2e-05 | 0.003554 |
17 | ENZYME LINKED RECEPTOR PROTEIN SIGNALING PATHWAY | 29 | 689 | 1.887e-05 | 0.005165 |
18 | NEUROGENESIS | 47 | 1402 | 2.24e-05 | 0.005485 |
19 | NEGATIVE REGULATION OF RESPONSE TO STIMULUS | 46 | 1360 | 2.216e-05 | 0.005485 |
20 | NEGATIVE REGULATION OF PHOSPHORYLATION | 21 | 422 | 2.572e-05 | 0.005698 |
21 | POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 37 | 1004 | 2.534e-05 | 0.005698 |
22 | REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT | 53 | 1672 | 2.966e-05 | 0.006274 |
23 | PROTEIN MODIFICATION BY SMALL PROTEIN CONJUGATION OR REMOVAL | 33 | 873 | 4.337e-05 | 0.008773 |
24 | POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS | 48 | 1492 | 5.123e-05 | 0.009931 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | ENZYME BINDING | 63 | 1737 | 4.335e-08 | 2.014e-05 |
2 | PROTEIN SERINE THREONINE KINASE ACTIVITY | 27 | 445 | 3.572e-08 | 2.014e-05 |
3 | PROTEIN KINASE ACTIVITY | 32 | 640 | 1.725e-07 | 3.645e-05 |
4 | KINASE ACTIVITY | 38 | 842 | 1.61e-07 | 3.645e-05 |
5 | TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 42 | 992 | 1.962e-07 | 3.645e-05 |
6 | TRANSLATION REPRESSOR ACTIVITY | 6 | 20 | 9.731e-07 | 0.0001507 |
7 | GROWTH FACTOR BINDING | 12 | 123 | 2.119e-06 | 0.0002812 |
8 | UBIQUITIN LIKE PROTEIN TRANSFERASE ACTIVITY | 22 | 420 | 7.437e-06 | 0.0008636 |
9 | TRANSMEMBRANE RECEPTOR PROTEIN KINASE ACTIVITY | 9 | 81 | 1.4e-05 | 0.001301 |
10 | KINASE BINDING | 27 | 606 | 1.362e-05 | 0.001301 |
11 | TRANSLATION REGULATOR ACTIVITY | 6 | 35 | 3.251e-05 | 0.00255 |
12 | PDZ DOMAIN BINDING | 9 | 90 | 3.294e-05 | 0.00255 |
13 | SMAD BINDING | 8 | 72 | 4.217e-05 | 0.003014 |
14 | RIBONUCLEOTIDE BINDING | 56 | 1860 | 7.122e-05 | 0.004726 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | TRANSFERASE COMPLEX | 34 | 703 | 1.53e-07 | 8.932e-05 |
2 | PML BODY | 11 | 97 | 1.27e-06 | 0.0003709 |
3 | UBIQUITIN LIGASE COMPLEX | 16 | 262 | 2.11e-05 | 0.003081 |
4 | CULLIN RING UBIQUITIN LIGASE COMPLEX | 12 | 150 | 1.652e-05 | 0.003081 |
Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|---|
1 | FoxO_signaling_pathway_hsa04068 | 11 | 132 | 2.537e-05 | 0.001066 | |
2 | Signaling_pathways_regulating_pluripotency_of_stem_cells_hsa04550 | 11 | 139 | 4.099e-05 | 0.001066 | |
3 | MAPK_signaling_pathway_hsa04010 | 16 | 295 | 8.736e-05 | 0.001514 | |
4 | Cellular_senescence_hsa04218 | 11 | 160 | 0.000146 | 0.001788 | |
5 | cGMP_PKG_signaling_pathway_hsa04022 | 11 | 163 | 0.000172 | 0.001788 | |
6 | HIF_1_signaling_pathway_hsa04066 | 7 | 100 | 0.002107 | 0.01826 | |
7 | Rap1_signaling_pathway_hsa04015 | 10 | 206 | 0.004033 | 0.02961 | |
8 | PI3K_Akt_signaling_pathway_hsa04151 | 14 | 352 | 0.004555 | 0.02961 | |
9 | Hippo_signaling_pathway_hsa04390 | 8 | 154 | 0.006535 | 0.03776 | |
10 | Jak_STAT_signaling_pathway_hsa04630 | 8 | 162 | 0.008761 | 0.04292 | |
11 | Ras_signaling_pathway_hsa04014 | 10 | 232 | 0.009079 | 0.04292 | |
12 | Regulation_of_actin_cytoskeleton_hsa04810 | 9 | 208 | 0.01268 | 0.05496 | |
13 | mTOR_signaling_pathway_hsa04150 | 7 | 151 | 0.01891 | 0.07161 | |
14 | Sphingolipid_signaling_pathway_hsa04071 | 6 | 118 | 0.01928 | 0.07161 | |
15 | Gap_junction_hsa04540 | 5 | 88 | 0.02069 | 0.07172 | |
16 | Phosphatidylinositol_signaling_system_hsa04070 | 5 | 99 | 0.03231 | 0.1018 | |
17 | p53_signaling_pathway_hsa04115 | 4 | 68 | 0.03329 | 0.1018 | |
18 | Adherens_junction_hsa04520 | 4 | 72 | 0.03982 | 0.115 | |
19 | TNF_signaling_pathway_hsa04668 | 5 | 108 | 0.04435 | 0.117 | |
20 | ABC_transporters_hsa02010 | 3 | 45 | 0.04613 | 0.117 | |
21 | Wnt_signaling_pathway_hsa04310 | 6 | 146 | 0.04726 | 0.117 | |
22 | Hedgehog_signaling_pathway_hsa04340 | 3 | 47 | 0.05138 | 0.1214 | |
23 | Cytokine_cytokine_receptor_interaction_hsa04060 | 9 | 270 | 0.05404 | 0.1222 | |
24 | TGF_beta_signaling_pathway_hsa04350 | 4 | 84 | 0.06347 | 0.1314 | |
25 | cAMP_signaling_pathway_hsa04024 | 7 | 198 | 0.06525 | 0.1314 | |
26 | ErbB_signaling_pathway_hsa04012 | 4 | 85 | 0.06571 | 0.1314 | |
27 | Tight_junction_hsa04530 | 6 | 170 | 0.08474 | 0.1632 | |
28 | VEGF_signaling_pathway_hsa04370 | 3 | 59 | 0.0884 | 0.1642 | |
29 | Apelin_signaling_pathway_hsa04371 | 5 | 137 | 0.09914 | 0.1778 | |
30 | Phospholipase_D_signaling_pathway_hsa04072 | 5 | 146 | 0.1209 | 0.2096 | |
31 | Focal_adhesion_hsa04510 | 6 | 199 | 0.1466 | 0.2459 | |
32 | AMPK_signaling_pathway_hsa04152 | 4 | 121 | 0.1708 | 0.2776 | |
33 | Autophagy_animal_hsa04140 | 4 | 128 | 0.1958 | 0.3085 | |
34 | Calcium_signaling_pathway_hsa04020 | 5 | 182 | 0.2262 | 0.346 | |
35 | Lysosome_hsa04142 | 3 | 123 | 0.3767 | 0.5362 | |
36 | Cell_cycle_hsa04110 | 3 | 124 | 0.3816 | 0.5362 | |
37 | Oocyte_meiosis_hsa04114 | 3 | 124 | 0.3816 | 0.5362 | |
38 | Peroxisome_hsa04146 | 2 | 83 | 0.4378 | 0.5685 | |
39 | Endocytosis_hsa04144 | 5 | 244 | 0.4413 | 0.5685 | |
40 | Apoptosis_hsa04210 | 3 | 138 | 0.4482 | 0.5685 | |
41 | Phagosome_hsa04145 | 3 | 152 | 0.5118 | 0.6214 | |
42 | Necroptosis_hsa04217 | 3 | 164 | 0.5631 | 0.6655 |
Num | lncRNA | miRNAs | miRNAs count | Gene | Sponge regulatory network | lncRNA log2FC | lncRNA pvalue | Gene log2FC | Gene pvalue | lncRNA-gene Pearson correlation |
---|---|---|---|---|---|---|---|---|---|---|
1 | RP11-119D9.1 | hsa-miR-106b-5p;hsa-miR-132-3p;hsa-miR-148b-3p;hsa-miR-15b-3p;hsa-miR-181b-5p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-25-3p;hsa-miR-425-5p;hsa-miR-93-5p | 10 | PTEN | Sponge network | -2.765 | 0 | -0.546 | 0 | 0.375 |
2 | LDLRAD4-AS1 | hsa-miR-106b-5p;hsa-miR-132-3p;hsa-miR-148b-3p;hsa-miR-15b-3p;hsa-miR-181b-5p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-25-3p;hsa-miR-589-3p;hsa-miR-93-5p | 10 | PTEN | Sponge network | -3.366 | 0 | -0.546 | 0 | 0.292 |
3 | RP11-166D19.1 | hsa-miR-106b-5p;hsa-miR-130b-3p;hsa-miR-148b-3p;hsa-miR-15b-3p;hsa-miR-16-2-3p;hsa-miR-186-5p;hsa-miR-193a-3p;hsa-miR-21-5p;hsa-miR-25-3p;hsa-miR-425-5p;hsa-miR-484;hsa-miR-589-3p;hsa-miR-590-3p;hsa-miR-590-5p | 14 | PTEN | Sponge network | -0.244 | 0.28835 | -0.546 | 0 | 0.28 |
4 | LINC01018 | hsa-miR-106b-5p;hsa-miR-132-3p;hsa-miR-148b-3p;hsa-miR-15b-3p;hsa-miR-181b-5p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-25-3p;hsa-miR-589-3p;hsa-miR-93-5p | 10 | PTEN | Sponge network | -3.231 | 0 | -0.546 | 0 | 0.256 |